3658 results for «391»
3658 results
Transcatheter tricuspid valve replacement - Where are we in Latin America?
12 Sep 2025 – From PCR Rio Valves 2025
Stay abreast of the latest advances in transcatheter tricuspid valve replacement (TTVR) across Latin America. This session highlights orthotopic implant technologies, patient selection criteria, early clinical outcomes, and discusses future perspectives including training, technology access, and regional clinical impact.
Management of residual and recurrent mitral regurgitation after TEER
12 Sep 2025 – From PCR Rio Valves 2025
Delve into the complexities of managing residual and recurrent mitral regurgitation following Transcatheter Edge-to-Edge Repair (TEER). This session discusses challenges such as late mitral regurgitation, strategies for handling single leaflet detachment, and anatomical considerations that may preclude TEER feasibility.
Extreme TAVI: bicuspid valves, emergency TAVI, dissections and more
12 Sep 2025 – From PCR Rio Valves 2025
Explore extreme and complex TAVI cases that push procedural limits, including urgent interventions, bicuspid valve sizing, valve-in-valve strategies, and rare complications such as type A dissection and late coronary occlusion. This session shares valuable clinical experiences and lessons from challenging scenarios.
Integrating the newest valve guidelines into daily clinical reality
12 Sep 2025 – From PCR Rio Valves 2025
Integrate the 2025 EACTS valve guidelines into your clinical practice with a focus on valvular heart disease management tailored to Latin American realities. This session reviews the most relevant updates on aortic stenosis management and transcatheter approaches for mitral and tricuspid valves.
Watch the interview with Fabien...
Tricuspid valve - Present and future perspectives: a critical appraisal
12 Sep 2025 – From PCR Rio Valves 2025
Explore the cutting-edge developments and practical insights in tricuspid valve interventions in this comprehensive session. Learn about the current status and patient selection for orthotopic valve implantation, gain expert guidance on intraprocedural monitoring with step-by-step tips, and understand the critical information required for pre, intra, and...
Structural heart: demanding anatomies, difficult situations and unusual strategies
12 Sep 2025 – From PCR Rio Valves 2025
Navigate complex structural heart interventions through this session focusing on challenging anatomies and innovative procedural strategies. Topics include orthotopic tricuspid valve replacement amidst anatomical and physiological complexities, percutaneous closure of Valsalva sinus fistula, extreme TAVI approaches for pure aortic regurgitation, management of mitral paravalvular leaks with...
TAVI - Take the first step considering life time management
12 Sep 2025 – From PCR Rio Valves 2025
Understand the critical importance of lifetime management in TAVI, emphasizing how the initial procedure impacts long-term results. This session discusses implantation depth, commissural alignment, and their roles beyond coronary access, illustrated through a low-risk young patient case and current durability data.
Advanced TAVI: techniques, timing, and problem-solving
12 Sep 2025 – From PCR Rio Valves 2025
Advance your knowledge in TAVI with this session addressing sophisticated techniques, procedural timing, and problem-solving in complex cases. Explore TAVI applications in rare quadricuspid valve anatomy with pure aortic insufficiency, strategic decision-making between TAVI and PCI, and innovative solutions for managing aortic stenosis in patients with...
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications
22 Mar 2022
Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.
Author
EuroPCR 2026 – Coronary revascularisation in patients undergoing TAVI
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is an individual participant data meta-analysis of 4 randomised controlled trials...
EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...
GLORIOUS - Efficacy of restrictive versus liberal oxygenation or Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomised clinical trial
21 Nov 2024
Edoardo Zancanaro provides his take on the GLORIOUS trial presented by Sebastian Wiberg at AHA 2024 in Chicago.
Author
Transcatheter aortic valve implantation without routine percutaneous coronary intervention: A randomized controlled trial (PRO-TAVI Trial)
29 Mar 2026
Jonathan Curio provides his take on the PRO-TAVI trial presented by Michiel Voskuil at ACC.26 in New Orleans and simultaneously published in The Lancet.
Author
Aortic stenosis and coronary artery disease: which should be treated first?
18 Jun 2026
In this review, Henryk Dreger explores the complex interplay between aortic stenosis and coronary artery disease, highlighting the latest evidence on PCI timing and its implications for clinical decision-making.
Author
The 2023 ESH Hypertension Guidelines revisit the role of renal denervation
05 Sep 2023
The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...
Author
Author
A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial
03 Apr 2026
Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...
Author
Author
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
02 Sep 2025
Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...
Author
